close

Agreements

Date: 2012-06-13

Type of information: R&D agreement

Compound: novel immunotherapies and especially auto antigen-specific immunotherapies

Company: Novo Nordisk (Denmark) JDRF - Juveniles Diabetes Research Foundation (USA)

Therapeutic area: Metabolic diseases

Type agreement:

R&D

Action mechanism:

Disease: type 1 diabetes

Details:

JDRF and Novo Nordisk are partnering to discover and develop novel immunotherapies to prevent, treat, and help cure type 1 diabetes. The two partners aim to address the underlying autoimmune process that is central to type 1 diabetes (T1D). Type 1 diabetes occurs when the body\'s immune system attacks and destroys the glucose-responsive, insulin-secreting beta cells of the pancreas, resulting in a lifetime requirement of insulin replacement therapy.
The collaboration between JDRF and Novo Nordisk will focus on research originating from academia, biotechnology companies and from internal research projects at Novo Nordisk. 
The collaboration with Novo Nordisk will be run out of the company’s newly opened Type 1 Diabetes R&D Center in Seattle. The Center, led by Dr Matthias von Herrath plans to employ 20 immunotherapy researchers working in Seattle supported by corporate R&D functions in Princeton, NJ and Denmark. The Center’s goal is to use translational research methods to rapidly move early-stage discovery projects in immunotherapy from animal models into small clinical exploratory trials in type 1 diabetes.

Financial terms:

Latest news:

Is general: Yes